GUILLAIN-BARRE SYNDROME RELATED TO THE APPLICATION OF VACCINE AGAINST SARS-CoV2 AND SEASONAL INFLUENZA. CASE REPORT

Authors

  • Juan Carlos López-Hernández Departamento de Urgencias Neurológicas / Clínica de Enfermedades Neuromusculares. Instituto Nacional de Neurología y Neurocirugía
  • Jorge López-Alderete Departamento de Neurología. Instituto Nacional de Neurología y Neurocirugía
  • Angel Escamilla-Ramírez Instituto Nacional de Neurología y Neurocirugía
  • Artemio Rosiles-Abonce Departamento de Neurología. Instituto Nacional de Neurología y Neurocirugía
  • Arturo Violante-Villanueva Departamento de Urgencias Neurológicas. Instituto Nacional de Neurología y Neurocirugía
  • Alonso Gutiérrez-Romero Departamento de Neurología. Instituto Nacional de Neurología y Neurocirugía
  • Steven Vargas-Cañas Clínica de Enfermedades Neuromusculares. Instituto Nacional de Neurología y Neurocirugía

DOI:

https://doi.org/10.31157/an.v27i2.348

Keywords:

SARS-CoV2, Influenza, Guillain Barre Syndrome, Vaccination, AIDP

Abstract

Summary: Guillain Barre Syndrome (GBS) is the leading cause of acute flaccid paralysis in the world. In the course of the pandemic influenza virus in previous decades and, currently, SARS-CoV2, an increased number of GBS cases have been reported coinciding with mass vaccination. Recently, vaccination against these two viruses has been implemented in the vaccination schedules of the adult population. Objective: to report a case of GBS related to vaccination against seasonal influenza virus and SARS-CoV2. We present the case of a 53-year-old woman with no history of infectious disease, who, after vaccination against seasonal influenza and SARS-CoV2 (Oxford/AstraZeneca) within 22 days of each other, began with progressive symptoms of weakness predominantly in the lower limbs, ascending. Clinically, GBS was integrated. In the paraclinical studies, she had a lumbar puncture with albumin-cytological dissociation, with a neuroconduction study that fulfils the criteria for an AIDP variant. Conclusion: to our knowledge, this is the first case of GBS related to both types of vaccine.

References

[1] van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469–82. https://doi.org/10.1038/nrneurol.2014.121.
[2] López-Hernández JC, Colunga-Lozano LE, Garcia-Trejo S, Gomez-Figueroa E, Delgado-Garcia G, Bazán-Rodríguez L, et al. Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barré syndrome, a single center experience. J Clin Neurosci Off J Neurosurg Soc Australas 2020;80:292–7. https://doi.org/10.1016/j.jocn.2020.04.059.
[3] Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599–612. https://doi.org/10.1016/j.vaccine.2010.06.003.
[4] López-Hernández J, Lisette B-R, Adib J de S, Eunice M-J, Elizabeth L-M, Erika G-L, et al. Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association? Neuroimmunol Reports 2022;2:100050. https://doi.org/10.1016/j.nerep.2021.100050.
[5] García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, Galnares-Olalde JA, Hernández-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol 2021;230:108818. https://doi.org/10.1016/j.clim.2021.108818.
[6] Asia C, Asia W. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Relev Epidemiol Hebd 2018;93:133–41.
[7] Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka K V, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780–8. https://doi.org/10.1002/ana.410440512.
[8] Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979;110:105–23. https://doi.org/10.1093/oxfordjournals.aje.a112795.
[9] Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Ann Neurol 2021;90:315–8. https://doi.org/10.1002/ana.26144.
[10] Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021;268:1133–70. https://doi.org/10.1007/s00415-020-10124-x.
[11] Lahoz Fernandez PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, Freitas Barboza IC, Vieira Silveira CG, et al. Guillain-Barre syndrome following COVID-19 vaccines: A scoping review. Acta Neurol Scand 2021. https://doi.org/10.1111/ane.13575.
[12] Langmuir AD, Bregman DJ, Kurland LT, Nathanson N, Victor M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984;119:841–79. https://doi.org/10.1093/oxfordjournals.aje.a113809.
[13] Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006;166:2217–21. https://doi.org/10.1001/archinte.166.20.2217.
[14] Kwong JC, Vasa PP, Campitelli MA, Hawken S, Wilson K, Rosella LC, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013;13:769–76. https://doi.org/10.1016/S1473-3099(13)70104-X.

Downloads

Additional Files

Published

2022-05-26

How to Cite

López-Hernández, J. C. ., López-Alderete, J., Angel, Rosiles-Abonce, A. ., Violante-Villanueva, A. ., Gutiérrez-Romero, A. ., & Vargas-Cañas, S. . (2022). GUILLAIN-BARRE SYNDROME RELATED TO THE APPLICATION OF VACCINE AGAINST SARS-CoV2 AND SEASONAL INFLUENZA. CASE REPORT. Archivos De Neurociencias, 27(2), 47–51. https://doi.org/10.31157/an.v27i2.348

Issue

Vol. 27 No. 2 (2022)

Section

Case report

License

Copyright (c) 2022 Juan Carlos López-Hernández, Jorge López-Alderete, Angel Escamilla-Ramírez, Artemio Rosiles-Abonce, Arturo Violante-Villanueva, Alonso Gutiérrez-Romero, Steven Vargas-Cañas

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.

January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.

January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Most read articles by the same author(s)